

Background

PantoCIN is a phase II, randomised, double-blinded, placebo controlled, crossover trial to assess Pantoprazole's effectiveness as prophylaxis against delayed Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy. The study will recruit **160 patients** from sites across New Zealand. It is managed by Cancer Trials New Zealand and funded by:



New sites



to...


Taranaki Base Hospital

...who open to recruitment this month

Patient Reported Outcomes

PantoCIN is a PRO study!

This study depends on questionnaires returned by patients



Enter all returned questionnaires online:
www.HealthObs.com/PantoCin

Please inform patients that they can contact you if they need help completing their day 5 questionnaires


Guidance on using the apps is available in section 13 of your site file

29 patients recruited


Congratulations to **Dunedin Hospital** who recruited their first participant this month!

We need 160 patients recruited to the study to meet our recruitment target.

PantoCIN recruitment by month



PantoCIN rate of recruitment



Well done!




Auckland City Hospital & Palmerston North Hospital

who are our top two recruiters!

Top 10 tips:

1. Ensure both drug and questionnaire compliance are written in the patient's notes
2. Include there is a record of the mode of completion for patient questionnaires
3. Report all Adverse events, including those related to chemotherapy
4. If you are using a template for source data, consider including the wording/options for alcohol consumption field
5. Include a record of discussion of contraception in patient notes
6. Update the patient Master Randomisation list in your site file section 10
7. Add a copy of your locality application and Māori approval to your site file section 7
8. Send an updated copy of the delegation log to CTNZ as required, and add copies of CVs and GCP certs to your ISF
9. Receipt return / compliance of study drug
10. Include any relevant local SOPs or reference them in your ISF



Thanks to all who joined us for the PantoCIN site teleconference on 28 August. Six sites joined us to discuss the study. Some tips and discussion points are summarised here:

Screening logs should include patients who meet all of the inclusion criteria and one or more of the exclusion criteria


Physical examination: for PantoCIN we are collecting this data based on clinical indication /standard of care

Date of diagnosis: this should be the date of

End of study questionnaire can be completed at the end of study treatment

PantoCIN data manager, Robert Cartwright, delivered some training on ALEA. The feedback from attendees was that this was very useful, if you have new staff or would like to arrange a time to run through this training, then contact Robert r.cartwright@auckland.ac.nz or call 09 923 4200.

Do you need patient cards or questionnaires?
Contact us to be sent copies.



PantoCIN online...

You can now access study essential documents and newsletters at cancertrials.ac.nz Documents include the current Protocol and CRF guidance. These are password controlled and the password will be supplied to PantoCIN staff.

News from Twitter
@CancerTrialsNZ
follow us for
PantoCIN updates!



Contact us

For general trial management queries please contact us:

Louise.clement@auckland.ac.nz

Tel: 09 923 4626

Fax: 09 373 7927

www.cancertrialsnz.ac.nz

